Sam Watson Archives | Cannabiz

Rec-style branding risks undermining the industry, warns Bioxyne CEO

by Adam Sheldon March 12, 2026March 12, 2026

Recreational-style branding in Australia’s medicinal cannabis market risks undermining the sector’s credibility, according to Bioxyne chief […]

Bioxyne lifts FY26 guidance after margin growth in strong first half

by Steve Jones February 26, 2026February 26, 2026

Bioxyne enters Central American markets with pastille supply deal

by Steve Jones December 12, 2025December 12, 2025

News in brief: Legalise Cannabis ramps up criticism of Victorian government; MCA launches desktop guide for clinicians; Bioxyne secures A$1.7m for UK GMP facility

by Adam Sheldon November 17, 2025February 21, 2026

Breathe Life Sciences launches Curaleaf medical inhalation device

by Adam Sheldon November 3, 2025November 3, 2025

Record revenue for Bioxyne but cash deficit rises after flower investment

by Steve Jones October 30, 2025November 3, 2025

Cannabis executive salaries: who earned what in FY25

by Adam Sheldon October 22, 2025October 22, 2025

‘It’s super exciting’ – Breathe Life Sciences secures ARTG listings for Dr Watson range

by Adam Sheldon October 9, 2025October 13, 2025

Bioxyne stays on course to hit A$25m revenue guidance despite Q3 fall

by Steve Jones April 28, 2025April 28, 2025

Bioxyne inks $7m deal with NectarTek Australia

by Martin Lane April 3, 2025April 3, 2025